<DOC>
	<DOCNO>NCT00508157</DOCNO>
	<brief_summary>258 patient treat least 3 month oral olanzapine , risperidone quetiapine treatment schizophrenia currently present metabolic syndrome , randomize : ) aripiprazole 16 week , flexible dosing within range 10 30 mg daily ( QD ) ; ii ) continue 16 week atypical antipsychotic treatment prior study enrollment .</brief_summary>
	<brief_title>A Phase 4 Study Assess Effects Aripiprazole Versus Other Atypical Antipsychotics Treatment Schizophrenic Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients : schizophrenia treat olanzapine , risperidone , quetiapine least 3 month diagnosis metabolic syndrome treat 1 parameter metabolic syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>